CD40 Bispecific Antibody increase T cell anti-tumor activity

“Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies”

doi: 10.1136/jitc-2022-005018. PMID: 36323431 Karin Hägerbrand , Peter Ellmark, et al. J Immunother Cancer 2022 Nov;10(11):e005018

Tetrameric Bispecific antibodies specific to CD40 and either CD326(EpCAM) or CD66e(CEA) were tested on human cells in vitro and in a mouse model in vivo. Ancell CD40-muIg/Biotin (cat #504-030) was utilized as part of the RUBY bispecific anti-human CD40 antibody screening procedure. Bispecific antibodies more efficiently enabled tumor antigen presentation in vitro and in vivo compared to monospecific anti-CD40 antibody.

Related Ancell Products

Human CD40 recombinant protein and antibody

anti-human CD326(EpCAM) products

anti-human CD66e(CEA) products